Dyne Therapeutics (DYN) announced the appointment of Erick Lucera as CFO of Dyne, effective March 31. Lucera brings more than thirty years of financial, operational and investment experience in the life science industry to Dyne. Lucera joins Dyne from Editas Medicine (EDIT).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
- Buy Rating Affirmed for Dyne Therapeutics Amid Promising DYNE-251 Data and Strategic Milestones
- Promising Advancements and Strategic Positioning of Dyne Therapeutics’ DYNE-251: A Buy Rating Analysis
- Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
- Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating